CA2942166A1 - Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors - Google Patents
Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors Download PDFInfo
- Publication number
- CA2942166A1 CA2942166A1 CA2942166A CA2942166A CA2942166A1 CA 2942166 A1 CA2942166 A1 CA 2942166A1 CA 2942166 A CA2942166 A CA 2942166A CA 2942166 A CA2942166 A CA 2942166A CA 2942166 A1 CA2942166 A1 CA 2942166A1
- Authority
- CA
- Canada
- Prior art keywords
- hsv
- glycoprotein
- recombinant
- infection
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701074 Human alphaherpesvirus 2 Species 0.000 title claims abstract description 503
- 229960005486 vaccine Drugs 0.000 title claims abstract description 82
- 239000013598 vector Substances 0.000 title abstract description 3
- 210000002845 virion Anatomy 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 135
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- 241000700605 Viruses Species 0.000 claims description 84
- 208000015181 infectious disease Diseases 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 79
- 102000003886 Glycoproteins Human genes 0.000 claims description 75
- 108090000288 Glycoproteins Proteins 0.000 claims description 75
- 208000003322 Coinfection Diseases 0.000 claims description 56
- 238000012217 deletion Methods 0.000 claims description 55
- 230000037430 deletion Effects 0.000 claims description 55
- 239000000232 Lipid Bilayer Substances 0.000 claims description 50
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 47
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 47
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 37
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 230000003053 immunization Effects 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 24
- 208000037952 HSV-1 infection Diseases 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 20
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 claims description 17
- 108700019146 Transgenes Proteins 0.000 claims description 17
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 17
- 244000052769 pathogen Species 0.000 claims description 16
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 13
- 244000045947 parasite Species 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 12
- 210000004392 genitalia Anatomy 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 201000008827 tuberculosis Diseases 0.000 claims description 9
- 241000711950 Filoviridae Species 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 241000186362 Mycobacterium leprae Species 0.000 claims description 5
- 241000187492 Mycobacterium marinum Species 0.000 claims description 5
- 241000187917 Mycobacterium ulcerans Species 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000029812 viral genome replication Effects 0.000 claims description 5
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 4
- 241000713112 Orthobunyavirus Species 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 230000037452 priming Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 2
- 241000711828 Lyssavirus Species 0.000 claims description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241000589884 Treponema pallidum Species 0.000 claims description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 2
- 101150069921 S6 gene Proteins 0.000 claims 2
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- -1 virions thereof Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 45
- 241000700584 Simplexvirus Species 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 208000001688 Herpes Genitalis Diseases 0.000 description 14
- 201000004946 genital herpes Diseases 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000005000 reproductive tract Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 4
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 4
- 101710178472 Tegument protein Proteins 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 101150036031 gD gene Proteins 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 101800000342 Glycoprotein C Proteins 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 101710187780 Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000568 immunological adjuvant Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 210000000427 trigeminal ganglion Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 206010073931 Genital herpes simplex Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000020241 Neonatal disease Diseases 0.000 description 2
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 101150096955 US6 gene Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003622 anti-hsv Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NGGRGTWYSXYVDK-RRKCRQDMSA-N 4-amino-5-chloro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 NGGRGTWYSXYVDK-RRKCRQDMSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 208000007993 Kaposi Varicelliform Eruption Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 230000001113 coital effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010014197 eczema herpeticum Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940124725 herpes simplex vaccine Drugs 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946965P | 2014-03-03 | 2014-03-03 | |
| US61/946,965 | 2014-03-03 | ||
| US201462080663P | 2014-11-17 | 2014-11-17 | |
| US62/080,663 | 2014-11-17 | ||
| PCT/US2015/018272 WO2015134368A2 (en) | 2014-03-03 | 2015-03-02 | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2942166A1 true CA2942166A1 (en) | 2015-09-11 |
Family
ID=54055977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2942166A Pending CA2942166A1 (en) | 2014-03-03 | 2015-03-02 | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9999665B2 (enExample) |
| EP (2) | EP3113801B1 (enExample) |
| JP (3) | JP6652497B2 (enExample) |
| CN (2) | CN106456805B (enExample) |
| AU (2) | AU2015225499B2 (enExample) |
| CA (1) | CA2942166A1 (enExample) |
| WO (1) | WO2015134368A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10918712B2 (en) * | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| EP3113801B1 (en) | 2014-03-03 | 2020-10-07 | Albert Einstein College of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| CN119523873A (zh) | 2018-04-27 | 2025-02-28 | 克里斯托生物技术股份有限公司 | 用于美容性应用的编码一种或多种美容蛋白的重组核酸 |
| WO2019213305A1 (en) * | 2018-05-01 | 2019-11-07 | Albert Einstein College Of Medicine | HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE |
| WO2020056411A1 (en) * | 2018-09-14 | 2020-03-19 | Excell Biotech, Llc | Recombinant herpes simplex virus 1 (hsv-1) |
| CA3115530A1 (en) * | 2018-10-17 | 2020-04-23 | Albert Einstein College Of Medicine | Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc) |
| EP3906052A1 (en) * | 2019-01-03 | 2021-11-10 | Albert Einstein College of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
| CA3179416A1 (en) * | 2020-04-07 | 2021-10-14 | Albert Einstein College Of Medicine | Method of treating and preventing ocular disease with hsv-2 delta gd |
| AU2021281314A1 (en) * | 2020-05-29 | 2022-12-22 | Albert Einstein College Of Medicine | Methods of using HSV-2 single cycle virus delta-gD and HSV-2 recombinant glycoprotein D |
| EP4217472A1 (en) | 2020-09-24 | 2023-08-02 | Albert Einstein College of Medicine | Attb cell line, transgenic cell lines derived therefrom, and methods of making the same |
| WO2023245159A1 (en) * | 2022-06-16 | 2023-12-21 | Albert Einstein College Of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines |
| EP4565270A4 (en) * | 2022-08-05 | 2025-11-19 | Immvira Biopharmaceuticals Co Ltd | HERPES SIMPLEX VIRUS TYPE 1 VACCINE INCOMPETENT FOR REPLICATION |
| US20250222112A1 (en) * | 2022-10-14 | 2025-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Recombinant immune complexes targeting herpes simplex virus |
| WO2025231288A2 (en) | 2024-05-01 | 2025-11-06 | Viradigm, Inc. | Hsv vectors having improved safety profiles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT77014B (en) * | 1982-07-20 | 1986-01-24 | Molecular Genetics Inc | Production of herpes simplex viral proteins |
| NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
| EP0231209B1 (en) * | 1985-07-29 | 1991-02-06 | The Upjohn Company | Virus vaccine |
| US5646041A (en) * | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
| CA2158148A1 (en) * | 1993-03-19 | 1994-09-29 | Stephen Charles Inglis | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| US20030083289A1 (en) * | 1995-10-19 | 2003-05-01 | Boursnell Michael Edward Griffith | Herpesvirus vectors and their uses |
| CN1120238C (zh) * | 1998-05-04 | 2003-09-03 | 本元正阳基因技术股份有限公司 | 以粘粒为基础构建重组单纯疱疹病毒及其用途 |
| DE60026588T2 (de) | 1999-12-17 | 2007-01-18 | Wyeth Holdings Corp. | Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus |
| WO2005005637A2 (en) * | 2003-05-09 | 2005-01-20 | Medigene, Inc. | Herpes simplex virus comprising a genetically modified glycoprotein d |
| US6984492B2 (en) * | 2003-09-05 | 2006-01-10 | Talecris Biotherapeutics, Inc. | Methods and compositions for treating herpes infections |
| US20080089910A1 (en) | 2004-06-29 | 2008-04-17 | Visalli Et Al | Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof |
| WO2006013515A2 (en) | 2004-07-26 | 2006-02-09 | Koninklijke Philips Electronics N.V. | Decision support system for simulating execution of an executable clinical guideline |
| WO2008030560A2 (en) * | 2006-09-08 | 2008-03-13 | The Trustees Of The University Of Pennsyvania | Hsv-1 and hsv-2 vaccines and methods of use thereof |
| US8865185B2 (en) * | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
| US9284355B2 (en) * | 2006-12-28 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| WO2009089154A2 (en) * | 2008-01-03 | 2009-07-16 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| CN101288770A (zh) * | 2008-03-14 | 2008-10-22 | 浙江省医学科学院 | 新型单纯疱疹病毒ⅱ型dna疫苗 |
| ES2732815T3 (es) * | 2009-05-22 | 2019-11-26 | Genocea Biosciences Inc | Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria |
| IN2012DN03209A (enExample) * | 2009-09-18 | 2015-10-23 | Fraunhofer Usa Inc | |
| US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| EP3113801B1 (en) | 2014-03-03 | 2020-10-07 | Albert Einstein College of Medicine | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors |
-
2015
- 2015-03-02 EP EP15758673.6A patent/EP3113801B1/en active Active
- 2015-03-02 AU AU2015225499A patent/AU2015225499B2/en active Active
- 2015-03-02 EP EP20195405.4A patent/EP3943106A1/en active Pending
- 2015-03-02 CN CN201580022222.6A patent/CN106456805B/zh active Active
- 2015-03-02 CN CN201911344961.3A patent/CN110938604B/zh active Active
- 2015-03-02 WO PCT/US2015/018272 patent/WO2015134368A2/en not_active Ceased
- 2015-03-02 CA CA2942166A patent/CA2942166A1/en active Pending
- 2015-03-02 JP JP2016555659A patent/JP6652497B2/ja active Active
-
2016
- 2016-02-04 US US15/015,322 patent/US9999665B2/en active Active
-
2017
- 2017-03-10 US US15/455,495 patent/US10076568B2/en active Active
-
2018
- 2018-06-01 US US15/995,471 patent/US10391165B2/en active Active
-
2019
- 2019-07-30 US US16/526,056 patent/US10751411B2/en active Active
-
2020
- 2020-01-23 JP JP2020009043A patent/JP6844045B2/ja active Active
- 2020-08-10 AU AU2020217310A patent/AU2020217310B2/en active Active
- 2020-08-18 US US16/995,926 patent/US10980874B2/en active Active
-
2021
- 2021-02-24 JP JP2021026943A patent/JP7050193B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200376114A1 (en) | 2020-12-03 |
| EP3113801B1 (en) | 2020-10-07 |
| US10076568B2 (en) | 2018-09-18 |
| CN110938604A (zh) | 2020-03-31 |
| JP2017510262A (ja) | 2017-04-13 |
| WO2015134368A2 (en) | 2015-09-11 |
| WO2015134368A3 (en) | 2015-11-26 |
| EP3113801A2 (en) | 2017-01-11 |
| JP7050193B2 (ja) | 2022-04-07 |
| JP6652497B2 (ja) | 2020-02-26 |
| US10751411B2 (en) | 2020-08-25 |
| AU2020217310A1 (en) | 2020-08-27 |
| US20170202952A1 (en) | 2017-07-20 |
| JP2021088590A (ja) | 2021-06-10 |
| AU2020217310B2 (en) | 2023-07-13 |
| US20160158343A1 (en) | 2016-06-09 |
| US20200023058A1 (en) | 2020-01-23 |
| JP2020079245A (ja) | 2020-05-28 |
| US9999665B2 (en) | 2018-06-19 |
| US20190111127A1 (en) | 2019-04-18 |
| EP3113801A4 (en) | 2017-10-25 |
| US10980874B2 (en) | 2021-04-20 |
| CN106456805B (zh) | 2020-01-10 |
| CN110938604B (zh) | 2024-04-05 |
| US10391165B2 (en) | 2019-08-27 |
| JP6844045B2 (ja) | 2021-03-17 |
| CN106456805A (zh) | 2017-02-22 |
| EP3943106A1 (en) | 2022-01-26 |
| AU2015225499B2 (en) | 2020-05-14 |
| AU2015225499A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020217310B2 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| US10918712B2 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors | |
| JP2024016032A (ja) | 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達 | |
| US20220088185A1 (en) | Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| HK40022690B (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 | |
| HK1229721B (zh) | 重组单纯疱疹病毒2(hsv-2)疫苗载体 | |
| WO2023245159A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines | |
| HK40022690A (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| HK1229721A1 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
| Santana et al. | Bicistronic DNA Vaccines Simultaneously Encoding HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200219 |
|
| EEER | Examination request |
Effective date: 20200219 |
|
| EEER | Examination request |
Effective date: 20200219 |
|
| EEER | Examination request |
Effective date: 20200219 |
|
| EEER | Examination request |
Effective date: 20200219 |
|
| EEER | Examination request |
Effective date: 20200219 |